An innovative approach has enabled scientists to detect free cancer cells in the bloodstream of patients with prostate cancer, breast cancer and pancreatic cancer that was previously unattainable. This gives hope to control the spread of cancer in real time, as well as learn how to prevent the development of resistance of the tumor.
In an article published in the latest issue of the journal established by IOP Publishing «Physical Biology», the authors describe innovative software that allows you to simultaneously handle the huge amount of data and detect in the blood whether there are rare tumor cells among millions of healthy people. Thus, it is possible not only with unprecedented accuracy and efficiency of detection of tumor cells, but also to monitor their movement from one tissue to other organs.
Billings Clinic oncologist and lead author Dr. Jorge Nieva commented the results: "Our technology will allow scientists to get away from the mice and cell cultures, and to send agents to their immediate objective, not allowing tumor cells to develop resistance."
"In the future, the developed method of liquid biopsy may change the approach to cancer treatment. Being close to the disease in real time, we will be able to make correct and timely decisions, including diagnosis, treatment options, and predictive analysis of the disease "- adds senior author of the technology, Professor Peter Kuhn.
Researchers from the Cancer Center at Scripps College, La Jolla (California) using a new technology were able to detect up to five times more cancer cells per milliliter of blood in 80% of 20 patients with prostate cancer, 70% of 30 patients with breast cancer and 50% of the 18 patients with pancreatic cancer.
The new technology is based on the fact that the fluorescent coloring agent added antibodies that “detect” proteins produced by cancer cells, and are attached to them, allowing you to effectively analyze the promotion and development of cancer cells. "Thus, we get a detailed portrait of harmful cells caught in the dissemination of the body. Never before we could not even dream about it "- says an expert on diagnostics, the leading researcher of the team Kuhn, Kelly Bethel.